107 related articles for article (PubMed ID: 26548578)
1. Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth.
Saitoh Y; Setoguchi T; Nagata M; Tsuru A; Nakamura S; Nagano S; Ishidou Y; Nagao-Kitamoto H; Yokouchi M; Maeda S; Tanimoto A; Furukawa T; Komiya S
Int J Oncol; 2016 Jan; 48(1):235-42. PubMed ID: 26548578
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.
Nakamura S; Nagano S; Nagao H; Ishidou Y; Yokouchi M; Abematsu M; Yamamoto T; Komiya S; Setoguchi T
PLoS One; 2013; 8(7):e69466. PubMed ID: 23861973
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma.
Bureta C; Saitoh Y; Tokumoto H; Sasaki H; Maeda S; Nagano S; Komiya S; Taniguchi N; Setoguchi T
Oncol Rep; 2019 Jun; 41(6):3404-3412. PubMed ID: 31002372
[TBL] [Abstract][Full Text] [Related]
4. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment.
Li XS; Li WQ; Wang WB
Cancer Biother Radiopharm; 2007 Dec; 22(6):772-8. PubMed ID: 18158768
[TBL] [Abstract][Full Text] [Related]
5. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
6. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
[TBL] [Abstract][Full Text] [Related]
7. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
8. Tranilast enhances the effect of anticancer agents in osteosarcoma.
Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
[TBL] [Abstract][Full Text] [Related]
9. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Lee PC; Kakadiya R; Su TL; Lee TC
Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
[TBL] [Abstract][Full Text] [Related]
12. The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
Yu R; Wang D; Ren X; Zeng L; Liu Y
Leuk Res; 2014 Sep; 38(9):1085-90. PubMed ID: 24908354
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
14. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
16. GLI2 is a novel therapeutic target for metastasis of osteosarcoma.
Nagao-Kitamoto H; Nagata M; Nagano S; Kitamoto S; Ishidou Y; Yamamoto T; Nakamura S; Tsuru A; Abematsu M; Fujimoto Y; Yokouchi M; Kitajima S; Yoshioka T; Maeda S; Yonezawa S; Komiya S; Setoguchi T
Int J Cancer; 2015 Mar; 136(6):1276-84. PubMed ID: 25082385
[TBL] [Abstract][Full Text] [Related]
17. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
18. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
[TBL] [Abstract][Full Text] [Related]
20. ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs.
Kleinsimon S; Kauczor G; Jaeger S; Eggert A; Seifert G; Delebinski C
BMC Complement Altern Med; 2017 Jan; 17(1):26. PubMed ID: 28061770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
